# EDGAR Filing Document

**Accession Number:** 0001898416
**File Stem:** 0001936288-26-000004
**Filing Date:** 2026-3
**Character Count:** 17816
**Document Hash:** 07e1dcea8d846f3b71ed6f0b6a151454
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001936288-26-000004.hdr.sgml**: 20260312

**ACCESSION NUMBER**: 0001936288-26-000004

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260312

**DATE AS OF CHANGE**: 20260312

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alvotech
- **CENTRAL INDEX KEY:** 0001898416
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981629342
- **STATE OF INCORPORATION:** N4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93700
- **FILM NUMBER:** 26747737

**BUSINESS ADDRESS:**
- **STREET 1:** 9, RUE DE BITBOURG
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-1273
- **BUSINESS PHONE:** 354 422-4500

**MAIL ADDRESS:**
- **STREET 1:** 9, RUE DE BITBOURG
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-1273

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alvotech Lux Holdings S.A.S.
- **DATE OF NAME CHANGE:** 20211209
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aztiq Pharma Partners S.a r.l.
- **CENTRAL INDEX KEY:** 0001936288

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** N4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 5, RUE HEIENHAFF
- **STREET 2:** L-1736 SENNINGERBERG
- **CITY:** GRAND DUCHY
- **STATE:** N4
- **ZIP:** 00000
- **BUSINESS PHONE:** 359 691 211 663

**MAIL ADDRESS:**
- **STREET 1:** 5, RUE HEIENHAFF
- **STREET 2:** L-1736 SENNINGERBERG
- **CITY:** GRAND DUCHY
- **STATE:** N4
- **ZIP:** 00000

## Exhibit 99.1

EXHIBIT 99.1

JOINT FILING AGREEMENT

This Joint Filing Agreement, dated as of March 12, 2026, is by and among Aztiq Pharma Partners S.à r.l., Aztiq Fund I SCSp, Floki GP S.à r.l., ATP ehf. and ATP Holdings ehf. (collectively, the "Filers").

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to the ordinary shares, with a nominal value of $0.01 per share, of Alvotech beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Aztiq Pharma Partners S.à r.l.**<br>By:<br> <u>/s/ David Olafsson</u><br> Name: David Olafsson<br> Title: Manager<br>By:<br> <u>/s/ Robert Wessman</u><br> Name: Robert Wessman<br> Title: Manager<br>**Aztiq Fund I SCSp**<br>By: <br> Floki GP S.à r.l.<br> its <br> General Partner<br>By:<br> <u>/s/ David Olafsson</u><br> Name: David Olafsson<br> Title: Manager<br>By:<br> <u>/s/ Robert Wessman</u><br> Name: Robert Wessman<br> Title: Manager<br>**Floki GP S.à r.l.**<br>By:<br> <u>/s/ David Olafsson</u><br> Name: David Olafsson<br> Title: Manager<br>By:<br> <u>/s/ Robert Wessman</u><br> Name: Robert Wessman<br> Title: Manager | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**ATP ehf.**<br>By:<br> <u>/s/ David Olafsson</u><br> Name: David Olafsson<br> Title: Director<br>By:<br> <u>/s/ Robert Wessman</u><br> Name: Robert Wessman<br> Title: Director<br>**ATP Holdings ehf.**<br>By:<br> <u>/s/ David Olafsson</u><br> Name: David Olafsson<br> Title: Director<br>By:<br> <u>/s/ Robert Wessman</u><br> Name: Robert Wessman<br> Title: Director |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Alvotech**

*(Name of Issuer)*

**Ordinary Shares, nominal value of $0.01 per share**

*(Title of Class of Securities)*

**L01800108**

*(CUSIP Number)*

**Danny Major**<br>Aztiq Pharma Partners S.a r.l.<br>5, rue Heienhaff<br>Senningerberg N4 L-1736<br>352 691 211 663

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/17/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **L01800108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Aztiq Pharma Partners S.a r.l.** | Name of reporting person<br>**Aztiq Pharma Partners S.a r.l.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**N4** | Citizenship or place of organization<br>**N4** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**103849420.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**95213851.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**103849420.00** | Aggregate amount beneficially owned by each reporting person<br>**103849420.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**33.3%** | Percent of class represented by amount in Row (11)<br>**33.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **L01800108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Aztiq Fund I SCSp** | Name of reporting person<br>**Aztiq Fund I SCSp** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**N4** | Citizenship or place of organization<br>**N4** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**103849420.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**95213851.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**103849420.00** | Aggregate amount beneficially owned by each reporting person<br>**103849420.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**33.3%** | Percent of class represented by amount in Row (11)<br>**33.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **L01800108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Floki GP S.a r.l.** | Name of reporting person<br>**Floki GP S.a r.l.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**N4** | Citizenship or place of organization<br>**N4** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**103849420.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**95213851.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**103849420.00** | Aggregate amount beneficially owned by each reporting person<br>**103849420.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**33.3%** | Percent of class represented by amount in Row (11)<br>**33.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **L01800108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ATP ehf.** | Name of reporting person<br>**ATP ehf.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**K6** | Citizenship or place of organization<br>**K6** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3003290.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3003290.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3003290.00** | Aggregate amount beneficially owned by each reporting person<br>**3003290.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.0%** | Percent of class represented by amount in Row (11)<br>**1.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **L01800108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ATP Holdings ehf.** | Name of reporting person<br>**ATP Holdings ehf.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**K6** | Citizenship or place of organization<br>**K6** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**17571.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3003290.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**17571.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3003290.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3020861.00** | Aggregate amount beneficially owned by each reporting person<br>**3020861.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.0%** | Percent of class represented by amount in Row (11)<br>**1.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, nominal value of $0.01 per share

**(b) Name of Issuer:**
Alvotech

**(c) Address of Issuer's Principal Executive Offices:**
9, Rue de Bitbourg, Luxembourg, N4, L-1273

This Amendment No. 3 (this "Amendment No. 3" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on July 5, 2022, and amended on July 18, 2022 and July 3, 2024 (as amended, the "Statement") by Aztiq Pharma Partners S.a r.l., Aztiq Fund I SCSp, Floki GP S.a r.l. and ATP Holdings ehf. Unless otherwise defined herein, capitalized terms used in this Amendment No. 3 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D/A set forth the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon the sum of (i) 312,021,375 Ordinary Shares outstanding as of December 31, 2025, as reported by the Issuer to the Reporting Persons; and (ii) 17,571 Ordinary shares issuable upon the exercise of Bondholder Warrants.

**(b)**
Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D/A set forth the number of Ordinary Shares as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.

**(c)**
Except as set forth herein, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Aztiq Pharma Partners S.a r.l.

**Signature:** /s/ David Olafsson

**Name/Title:** By David Olafsson, Manager

**Date:** 03/12/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Aztiq Fund I SCSp

**Signature:** /s/ David Olafsson

**Name/Title:** By Floki GP S.a r.l., its general partner, By David Olafsson, Manager

**Date:** 03/12/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Floki GP S.a r.l.

**Signature:** /s/ David Olafsson

**Name/Title:** By David Olafsson, Manager

**Date:** 03/12/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ATP ehf.

**Signature:** /s/ David Olafsson

**Name/Title:** By David Olafsson, Director

**Date:** 03/12/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ATP Holdings ehf.

**Signature:** /s/ David Olafsson

**Name/Title:** By David Olafsson, Director

**Date:** 03/12/2026